The preterm infant is often exposed to maternal and neonatal inflammatory stimuli and is born with immature lungs, resulting in a need for oxygen therapy. Nutritional intervention with docosahexaenoic acid (DHA; 6.3 g/kg of diet) has been shown to attenuate inflammation in various human diseases. Previous studies demonstrated that maternal DHA supplementation during late gestation and lactation attenuated hyperoxic lung injury in newborn mouse pups. In the present studies, we tested the hypothesis that DHA supplementation to the dam would reduce hyperoxic lung injury and growth deficits in a more severe model of systemic maternal inflammation, including LPS and neonatal hyperoxia exposure. On embryonic day 16, dams were placed on DHA (6.3 g DHA/kg diet) or control diets and injected with saline or LPS. Diets were maintained through weaning. At birth, pups were placed in room air or hyperoxia for 14 d. Improvements in birth weight (P < 0.01), alveolarization (P # 0.01), and pulmonary function (P # 0.03) at 2 and 8 wk of age were observed in pups exposed to perinatal inflammation and born to DHA-supplemented dams compared with control diet-exposed pups. These improvements were associated with decreases in tissue macrophage numbers (P < 0.01), monocyte chemoattractant protein-1 expression (P # 0.05), and decreases in soluble receptor for advanced glycation end products levels (P < 0.01) at 2 and 8 wk. Furthermore, DHA supplementation attenuated pulmonary fibrosis, which was associated with the reduction of matrix metalloproteinases 2, 3, and 8 (P # 0.03) and collagen mRNA (P # 0.05), and decreased collagen (P < 0.01) and vimentin (P # 0.03) protein concentrations. In a model of severe inflammation, maternal DHA supplementation lessened inflammation and improved lung growth in the offspring. Maternal supplementation with DHA may be a therapeutic strategy to reduce neonatal inflammation. J. Nutr.
Introduction
Recent advances in neonatal care have resulted in the survival of infants after shorter gestation and with lower birth weights. These infants sometimes succumb to severe lung disease with extended stays in the neonatal intensive care unit at enormous financial cost (1, 2) . Severely affected infants have decreased alveolarization, as observed in mild and moderate bronchopulmonary dysplasia, but they also develop interstitial lung fibrosis, have permanently altered pulmonary physiology, are more susceptible to respiratory infections, and are much more likely to require long-term pulmonary care (3) (4) (5) (6) . The association between maternal inflammation, intrauterine growth restriction, and preterm birth has been recognized in recent years (7) (8) (9) (10) . However, fetal and neonatal consequences of adverse maternal environments have not been investigated extensively. Previously, we established a murine model of systemic maternal inflammation followed by neonatal hyperoxia exposure to better understand the complex spectrum of morbidities associated with combined perinatal exposures (11) (12) (13) . The resulting pulmonary phenotypes are unique in that the lungs of the mouse pups exposed to both maternal inflammation and neonatal hyperoxia were more dense, with diffuse interstitial fibrosis, and more severe deficits in alveolarization than mice exposed to either a single exposure alone or the control group.
Infiltration of inflammatory cells is a hallmark of both neonatal lung injury and pulmonary fibrosis. Studies have indicated that several anti-inflammatory therapies that decreased the accumulation of inflammatory cells also improved pulmonary development (14, 15) . Pulmonary macrophages express transforming growth factor beta (TGF-b) 7 and matrix metalloproteinases (MMPs), affecting the surrounding cellular structure (16) and resulting in pulmonary fibrosis. Mice exposed to both maternal inflammation and neonatal hyperoxia exhibit a persistent elevation in pulmonary macrophage numbers into adulthood (13) .
The receptor for advanced glycation end products (RAGE) is found in the alveolar epithelium, is expressed on the surface of macrophages, and is highly associated with lung homeostasis (17) . RAGE can be membrane-bound and function in receptor signaling, or it can be cleaved by proteases and function as a decoy receptor or bind to integrins on macrophages and propagate inflammation (18, 19) . Increased plasma levels of cleaved or soluble RAGE (sRAGE) are associated with poor outcome in acute lung injury (20) and with alveolar epithelial injury in lung transplant patients (21) . In the lung, activation of RAGE through ligand binding is involved in expression of TGF-b and induction of the epithelial-to-mesenchymal transition (2) . However, the exact role of RAGE activation in the course of neonatal lung injury is not fully defined. Consequently, we investigated RAGE expression in our model.
Mesenchymal or interstitial cells within the alveolar area of the lung are a heterogeneous population consisting of fibrocytes, smooth muscle cells, and myofibroblasts that provide the extracellular matrix or scaffolding for lung growth and alveolarization (22) . During late alveolarization, the air sac interstitium undergoes thinning through extensive apoptosis of these mesenchymal cells. Altered regulation of interstitial cells, including proliferation or apoptosis of myofibroblasts, would result in an increase in markers, such as vimentin, a-smooth muscle actin, or collagen, and result in diffuse fibrosis.
Few therapies have proven efficacious in preventing hyperoxic lung injury. In previous studies, we reported that maternal dietary supplementation with DHA decreases inflammatory responses and improves lung growth in mouse pups exposed to hyperoxia alone (23) . The doses of DHA in our previous and present studies are designed to mimic a dose in humans of ;600 mg/d. This maternal dose yields liver concentrations in the pups of ;10 mmol/g liver (23) . In the present study, we tested the hypothesis that the diffusely fibrotic ''stiff'' lung and the deficits in alveolarization observed in adult mice exposed to maternal LPS and neonatal hyperoxia are associated with increased macrophage accumulation, matrix remodeling enzymes, and activation of TGF-b-mediated pathways, resulting in substantial collagen deposition. Furthermore, we hypothesized that this phenotype can be rescued by dietary administration of DHA to the pregnant and lactating dam.
Materials and Methods
Animals and exposure. Animal study protocols were approved by the Institutional Animal Care and Use Committee at The Research Institute at Nationwide ChildrenÕs Hospital (Columbus, OH). All animals were handled in accordance with NIH guidelines for ethical exposure, and mice were housed in a ''specific pathogen-free'' facility for at least 7 d before breeding was started. Pregnancy was time-dated by the presence of a vaginal plug (embryonic day 1). Pregnant C3H/HeN mice were injected on embryonic day 16 with LPS (80 mg/kg, i.p., serotype 0111: B4; catalog #437627; Calbiochem) or an equal volume of saline (11) (12) (13) . Also on embryonic day 16, pregnant dams receiving either LPS or saline were placed on control or DHA-supplemented diets, as described previously (23) . Briefly, the control and DHA diets were identical except that approximately half of the v-3 FA content in the DHA diet was DHA and the remaining half was linolenic acid, whereas in the control diet, the entire amount was linolenic acid. Each litter of newborn mice was paired with a litter born to a dam receiving the same embryonic day 16 exposures (LPS or saline, control or DHA diets), and the pups were pooled and redistributed randomly as described previously (11) . One of the paired groups of pups was exposed to 85% O 2 for 2 wk and subsequently returned to room air (RA), whereas the corresponding group was maintained in RA. Nursing dams were rotated between their RA and O 2 litter every 24 h to reduce O 2 toxicity. Twenty-four h of RA or O 2 exposure was designated as day 1. The mice were killed by ketamine/xylazine overdose; only 1 pup per litter was used at each time point for any given analysis, and equal numbers of males and females were used. For the pulmonary function tests, 1 male and 1 female were analyzed from each litter. A total of 20 litters and 1-2 pups per litter were used for analyses. In most cases, individual animals were used for each analysis because of the size limitations on the sample. For simplicity, the groups were designated control diet-saline/room air (C-S/RA), DHA diet-saline/room air (DHA-S/RA), control diet-LPS/ 85% oxygen (C-LPS/O 2 ), and DHA diet-LPS/85% oxygen (DHA-LPS/O 2 ). Body weights were assessed after birth and at 2 and 8 wk of age.
Histology. Tissue sections were prepared as described previously. (13) Histologic slides were stained with hematoxylin and eosin for morphometric measurements and MasonÕs trichrome and Picro-sirius red stains to assess collagen deposition. Morphometric and histochemical analyses of inflation-fixed and hematoxylin-and eosin-stained lung sections were performed at 2 and 8 wk of age.
Immunohistochemistry. Macrophage immunohistochemistry and cell counts were performed as described previously (13) .
Western immunoblotting. Frozen lungs were homogenized, and protein concentrations were determined by Bradford assay. Proteins were separated on SDS-PAGE gels and transferred to polyvinylidene difluoride membranes. Membranes were probed with primary antibodies to collagen I (ab292; Abcam), collagen III (234189; EMD Millipore), p-Smad2 (3108; Cell Signaling Technology), total Smad2/3 (3102; Cell Signaling Technology), or vimentin (3390; Cell Signaling Technology). Appropriate secondary antibodies were chosen for each primary. Blots were developed using enhanced chemiluminescence (ECL Western Blotting Detection; GE Healthcare), and expression levels were quantified using Image Quant software (version 5.0; Molecular Dynamics). The density of the band for the protein of interest was normalized to the density of b-actin protein (ab6276; Abcam).
Pulmonary function tests. Pulmonary function tests were performed as described previously (13) . At 2 wk of age, mice were tracheotomized with a 23-gauge cannula, and, at 8 wk of age, a 20-gauge cannula. For each parameter, 3 measurements were assessed and averaged. Measurements were excluded from analyses if disrupted by a spontaneous breath, and a coefficient of determination of 0.98 was used as the lower limit for each measurement.
ELISA. Frozen lungs were homogenized, and protein concentrations were determined by Bradford assay. sRAGE and monocyte chemoattractant protein-1 (MCP-1) concentrations were measured using ELISA (Duoset ELISA kits; R&D Systems) according to the protocols of the manufacturer. Absorbances were determined spectrophometrically using a Spectramax M2 Plate Reader (Molecular Devices). For the purposes of our study, we did not differentiate the cleaved from the alternatively transcribed forms and will refer to both as sRAGE.
Quantitative real-time PCR. The gelatinases Mmp2 and Mmp9 are involved in tissue repair and remodeling, and the collagenases Mmp3 and Mmp8 are active in tissue remodeling. The mRNA expression of these matrix remodeling enzymes, as well as the transforming growth factor Tgfb gene and the collagen I (Col1) and III (Col3) genes, was measured by quantitative real-time PCR as described previously (13) .
Statistics. Analyses were performed using GraphPad Prism 6 (GraphPad Software). Data are expressed as means 6 SEMs. Statistical analyses were performed using a 2-factor ANOVA and TukeyÕs post hoc test with the variables S/RA or LPS/O 2 as exposures and control or DHA as diets. P < 0.05 was considered statistically significant. All data were analyzed for equal variances, and, if indicated, the data were log transformed before performing the ANOVA.
Results
Birth weight. Maternal LPS injection reduced birth weight in C-LPS/O 2 pups compared with all other groups. At 2 and 8 wk of age, body weights were not different between the S/RA and LPS/O 2 groups. Maternal DHA supplementation prevented lower birth weights in pups born to LPS-injected dams ( Table 1) .
Morphometric assessment of alveolarization. Alveolarization was improved by maternal DHA supplementation in mice exposed to LPS/O 2 ( Fig. 1; Supplemental Fig. 1 ). LPS/O 2 exposure caused significantly fewer alveoli in pups nursed by control-and DHA-fed dams at 2 and 8 wk of age. However, the number of alveoli was significantly higher in DHA-LPS/O 2 -exposed pups than in C-LPS/O 2 -exposed pups at both time points (Fig. 1A, B) . The number of alveoli was not different in S/RA-exposed pups between diets at either 2 or 8 wk.
Pulmonary tests. Lung function was improved in the LPS/O 2 -exposed pups by maternal DHA supplementation ( Table 2) . Tissue resistance was increased in C-LPS/O 2 -exposed mice at 2 and 8 wk of age compared with the C-S/RA-or DHA-LPS/O 2 -exposed mice. Static compliance was decreased in C-LPS/O 2 -and DHA-LPS/O 2 -exposed mice at 2 wk compared with C-S/RA (Table 2) . At 8 wk, static compliance was decreased in the C-LPS/O 2 -exposed mice compared with the C-S/RA-and DHA-LPS/O 2 -exposed mice. Inspiratory capacity was decreased in C-LPS/O 2 -exposed mice at 2 and 8 wk of age compared with S/RA-exposed mice and decreased compared with DHA-LPS/O 2 -exposed mice at 8 wk (Table 2 ). No differences were observed between diets in the S/RA groups.
Macrophage Numbers. At 8 wk (6 wk after return to RA), the macrophage numbers were 18 times greater in the C-LPS/O 2 -exposed mice than in the S/RA groups ( Fig. 2; Supplemental Fig.  2 ). DHA supplementation during development dramatically lessened the numbers of macrophages after recovery. DHA supplementation in the LPS/O 2 -exposed group resulted in macrophage numbers that were 4-fold greater than the S/RAexposed groups. MCP-1 Concentrations. Consistent with the presence of macrophages in the lung tissues, MCP-1 protein concentrations were elevated in the bronchoalveolar lavage (BAL) at 2 wk in pups exposed to C-LPS/O 2 compared with S/RA-exposed groups and DHA-LPS/O 2 -exposed mice ( Table 3) . No differences in MCP-1 protein concentrations were observed in the BAL at 8 wk. At 2 wk, MCP-1 protein concentrations were elevated in LPS/O 2 -exposed lung tissues compared with the S/RA-exposed lungs regardless of diet. MCP-1 concentrations in the tissues of the C-LPS/O 2 -exposed mice at 8 wk were higher than the C-S/RA, but the MCP-1 concentrations in DHA-LPS/O 2 -exposed mice had returned to control levels. sRAGE measurement. At 2 wk, no differences were observed between exposure groups in BAL sRAGE concentrations (Table  3) . sRAGE concentrations were higher in the BAL of the C-LPS/ O 2 -exposed group than S/RA groups and the DHA-LPS/O 2 group. These data indicate that DHA supplementation prevented the increase in sRAGE concentrations observed in the C-LPS/O 2 group. No differences were observed in RAGE protein concentrations in the tissue homogenates at 2 or 8 wk (Table 3) , but RAGE concentrations tended to be lower in the C-LPS/O 2 than all other groups at 8 wk (P = 0.08).
MMP mRNA expression. Mmp2 mRNA levels were greater in DHA-LPS/O 2 -exposed pups at 7 and 14 d than in C-S/RA pups. In C-LPS/O 2 -exposed mice, Mmp2 mRNA levels were increased at day 14, but the increase was significantly lower than that observed in DHA-LPS/O 2 -exposed mice. Mmp9 levels were significantly increased in DHA-LPS/O 2 -exposed pups at d 7 only (Table 4) . Mmp3 and Mmp8 levels were increased in C-LPS/O 2 -exposed pups at day 1 and day 7 but were not different from S/RA at day 14 (Table 4) . A slight increase in Mmp3 was observed in DHA-LPS/O 2 -exposed pups at day 14.
TGF-b mRNA expression. Early time points were investigated for the expression of fibrotic markers that would alter lung structure. Tgfb mRNA was increased in C-LPS/O 2 -exposed mice at day 1, and this increase was prevented in the DHA-LPS/O 2 -exposed mice (Table 5) . Furthermore, by day 14, TGF-b expression was significantly decreased in DHA-LPS/O 2 -exposed mice compared with all other groups. Col1 mRNA was lower in C-LPS/O 2 -exposed pups at days 1 and 7 than in S/RA controls and DHA-LPS/O 2 -exposed pups (Table 5 ). Col3 mRNA was significantly increased in C-LPS/O 2 -exposed pups at days 1 and 7, and this increase was prevented by DHA supplementation in LPS/O 2 -exposed mice ( Table 5 ).
Phosphorylation of SMAD proteins. To evaluate TGF-b signaling, p-Smad2 and p-Smad3 protein concentrations were measured (Fig. 3) . At 2 wk, no differences in p-SMAD concentrations were observed among exposure groups (data not shown). At 8 wk, p-SMAD2 and p-SMAD3 concentrations were elevated in C-LPS/O 2 -exposed compared with C-S/RAexposed mice. DHA supplementation attenuated the increases in both p-SMAD2 and p-SMAD3 in LPS/O 2 -exposed mice (Fig. 3A, B) .
Histochemical assessment of fibrosis. Histochemical analyses of inflation-fixed tissue sections at 8 wk indicated greater collagen deposition in C-LPS/O 2 -exposed mice compared with DHA-LPS/O 2 , C-S/RA, and DHA-S/RA groups (Supplemental Fig. 3A and B) . There was a significant increase in collagen I at 8 wk and collagen III at 2 and 8 wk in C-LPS/O 2 -exposed compared with C-S/RA-exposed mice. Dietary DHA supplementation decreased LPS/O 2 -related increases in collagen deposition at 2 and 8 wk of age ( Table 6 ). Total area of collagen I and collagen III fluorescence was not different between DHA-LPS/ O 2 -exposed mice and S/RA-exposed controls (Table 6 ). Vimentin concentration were greater in C-LPS/O 2 -exposed mice than all other exposure groups at 2 and 8 wk (Table 6) .
Discussion
In previous studies, the combined treatments of maternal LPS injection and subsequent neonatal hyperoxia exposure resulted in greater reduction of alveolar numbers than either LPS or hyperoxia exposure alone (11, 13) . Furthermore, only the combined exposures exhibited pulmonary fibrosis and ongoing deficiencies in pulmonary function. These current studies focused on the combined exposures to evaluate the efficacy of maternal DHA supplementation on the development of perinatal inflammation-associated pulmonary fibrosis. Our mouse model of maternal LPS injection and neonatal hyperoxia exposure recapitulates the clinical circumstances and many of the pulmonary morbidities observed in a population of severely affected preterm infants (4, 5, 22) . In the present studies, we demonstrated that maternal DHA supplementation improved lung growth and function, decreased inflammatory responses, lessened the expression of matrix remodeling enzymes, and reduced markers of lung fibrosis.
Epidemiologic studies demonstrated a correlation between intrauterine growth restriction resulting in low birth weight and the development of pulmonary and cardiac diseases that manifest in adulthood (4,24). Premature and small-for-gestationalage infants exhibit pulmonary pathologies later in life, including wheezing, respiratory infections, and recurrent hospitalizations (4, 10, 25) . Interestingly, our model also demonstrated reduced birth weights in response to LPS injection (Table 1) , but the pups resumed normal weights by 14 d. The observed differences in birth weights may be attributable to maternal responses to inflammation that result in decreased nutrition to the fetus or a direct response from the fetus. Consistent with our previous reports, alveolarization was impaired by LPS/O 2 exposure at 8 wk ( Fig. 1; Supplemental Fig.  1 ) (13), but DHA supplementation attenuated this impairment. Similarly, pulmonary function tests indicated stiffer and less compliant lung tissue and smaller lung volumes in the LPS/O 2 group compared with all other groups ( Table 2) . DHA supplementation also prevented the alterations in lung function. Despite the more severe model, DHA supplementation improved both alveolarization and lung function.
Decreased macrophage infiltration was observed previously in the pups nursed by DHA-supplemented dams (23) , and similar effects were observed in this more severe inflammatory model ( Fig. 2; Supplemental Fig. 2 ). The influx of macrophages during neonatal inflammation and hyperoxia exposure contributes to lung injury and remodeling in humans and animal models (26, 27) . Our previous studies indicated that mouse pups that were exposed to both LPS and O 2 have even greater numbers of pulmonary macrophages than pups that were exposed to hyperoxia alone (13) . Our current data indicated that greater MCP-1 expression is observed in the LPS/O 2 -exposed mice, and this increase is attenuated by DHA supplementation (Table 3) . Greater numbers of macrophages early during injury and the persistence of the macrophages in the lungs of LPS/O 2 -exposed mice after recovery implied that the macrophages could be contributing to the more severe and persistent phenotype observed in this model. Furthermore, DHA supplementation reduces chemotaxis, possibly through attenuating MCP-1 expression.
Macrophages secrete MMPs that can disrupt basement membranes and/or cause changes in cytoskeletal arrangement to initiate repair mechanisms (16, 28) . Although many of the MMPs have been studied in the context of neonatal hyperoxic lung injury, the most extensively studied have been MMP-2, MMP-9, MMP-3, and MMP-8 (28). MMP-2 and MMP-9 are gelatinases and are expressed by neutrophils and epithelial cells. Interestingly, we observed no increases in gelatinases by LPS/O 2 exposure at any time points studied during the first 14 d of life, but both are increased by DHA supplementation (Table 4) . Hence, we speculate that the DHA-associated increased MMP-9 concentrations are attributable to initiation of repair mechanisms in response to injury. Collagenases MMP-3 and MMP-8 are dramatically increased by C-LPS/O 2 exposure, and the increases are attenuated in the DHA-LPS/O 2 -exposed pups ( Table 4 ). The early increases in MMP-3 and MMP-8 closely correlate with the early increases in collagen III (Table 5) ; however, both MMPs and collagen mRNAs were at control levels by day 14. These data would imply that the excess collagen deposition in lung tissues observed in the Picro-sirius red and trichrome staining are likely to be a consequence of early responses (Supplemental Figs. 3A and B) . In fact, elevated MMP-8 concentrations have been observed in humans and rodents that develop chronic lung disease (29, 30) . Collectively, these data would imply that the DHA-supplemented pups are able to better invoke repair mechanisms and/or prevent the permanent injury in the lung.
RAGE expression is found in pulmonary epithelial cells, monocytes, and macrophages (31) . RAGE is a danger-associated molecular pattern receptor and responds to cellular injury through binding ligands. Intracellular RAGE signaling has been associated with TGF-b expression and cytoskeletal remodeling during cell movement (32) . Alternatively, RAGE signaling is required for normal development and pulmonary homeostasis because RAGE knockout mice develop fibrotic lungs and have reduced numbers of alveolar type 1 and type 2 cells with an abnormal and fragmented basement membrane (33) . RAGE can be cleaved by proteases, such as MMPs, which result in a soluble form (sRAGE) (34, 35) . Our findings indicated that LPS and O 2 exposure caused an increase in the concentrations of sRAGE found in the BAL fluids (Table 3) . Although overall sRAGE concentrations are decreased by 8 wk, sRAGE concentrations remained higher in the C-LPS/O 2 -exposed group than all other groups. sRAGE can function as a decoy receptor, lessening the ligand-receptor signaling, but sRAGE can also bind to integrins 
Mmp2
Mmp9 Mmp3 Mmp8 on monocytes and macrophages and further potentiate chemotaxis (19, 36) . The persistence of increased sRAGE concentrations long after the inflammatory stimuli has ceased implies that sRAGE may be involved in low-level chronic inflammatory stimuli. DHA supplementation prevented the long-term increased expression of sRAGE, which is likely in part attributable to the decrease in macrophage numbers. TGF-b expression is closely associated with normal lung growth and wound healing. In our studies, we observed early increases in TGF-b mRNA expression at day 1 in LPS/O 2 -treated pups that were nursed by dams fed control diets, and the increase was prevented by DHA supplementation (Table 5) . Elevated expression of TGF-b mRNA expression was only observed at day 1 but temporally coincided with the increases in collagen III at days 1 and 7. Increased concentrations of SMAD2/3 phosphorylation, downstream effectors of TGF-b, were seen in adulthood at 8 wk of age in C-LPS/O 2 -exposed mice, indicating a change in the SMAD signaling pathways that persists into adulthood (Fig. 3) . The expression of collagen and many other matrix proteins are regulated by the TGF-b/SMAD2/3 pathway and may additively affect the fibrotic phenotype.
Changes in expression of collagens in the lungs of LPS/O 2 -treated pups during this developmental period are not straightforward. Collagen I mRNA expression was suppressed in C-LPS/ O 2 -exposed pups at days 1 and 7 (Table 5) . At these same time points, collagen III expression was enhanced in C-LPS/O 2 -exposed pups (Table 5 ). These alterations in collagen expression observed in C-LPS/O 2 -exposed mice were not observed in pups exposed to DHA-LPS/O 2 , indicating a preservation of lung architecture. Based on these data, we speculate that dysregulation of TGF-b, SMAD2/3, and/or collagen expression during the critical pulmonary developmental period taking place during the first 14 d of life in the mouse pups are likely to permanently affect the development of the lung. The changes in TGF-b expression, SMAD phosphorylation, and collagen expression were all prevented by DHA supplementation.
Last, we observed greater vimentin protein concentrations at 2 and 8 wk in C-LPS/O 2 -exposed mice than in the S/RA mice, but this response was substantially attenuated in the DHA-LPS/ O 2 -exposed mice (Table 6 ). These data would indicate greater numbers of myofibroblasts in the lungs of the C-LPS/O 2 -exposed mice and may contribute to the greater concentrations of collagen observed in these mice (Table 6 ) (37).
We established a murine model that recapitulated much of the pathophysiology that is observed in infants that develop long-term chronic lung disease. Our data indicated that the abnormalities observed in both lung structure and function at 8 wk of age in our LPS/O 2 -treated mice are a result of events that occur within the first 2 wk of life. In addition, we demonstrated that dampening the inflammatory responses during late gestation and early life by DHA supplementation improved pulmonary outcomes by lessening fibrotic responses and improved alveolarization (16) . Although DHA supplementation to pregnant and lactating mothers is currently recommended, the levels of supplementation are below those found to be efficacious in dampening inflammatory responses. Thus, our novel data strongly support the need for additional human studies to determine optimal DHA supplementation strategies to prevent respiratory disease in preterm infants. 
